

Effective October 1<sup>st</sup>, 2020, the NOA will be updated to a slightly different format.



RESEARCH  
Department of Health and Human Services  
National Institutes of Health

Notice of Award

Federal Award Date: 08/14/2017



NATIONAL CANCER INSTITUTE

**Grant Number:** 2R01CA120528-11A1

**FAIN:** R01CA120528

**Principal Investigator(s):**

RAPHAEL BUENO, MD

Name of Principle Investigator(s)

**Project Title:** Prospective Validation of Prognostic and Predictive Molecular tests in Mesothelioma

Ms. De Jesus, Maribel  
Senior Grants Administrator, Pre Award  
75 Francis Street  
Boston, MA 021156110

MGB Pre-Award Contact

**Award e-mailed to:** bwhgc@partners.org

Project Period Dates

**Period Of Performance:**

**Budget Period:** 08/14/2017 – 07/31/2018

**Project Period:** 04/07/2006 – 07/31/2022

Total Amount of Award

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of [REDACTED] (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to BRIGHAM AND WOMEN'S HOSPITAL in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA120528. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Info on NIH  
acknowledgement in  
Publications, Press Releases,  
etc.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Page-1

NIH NGA R | Version: 1 - 06/23/2017 11:27 00 | Generated on: 8/14/2017 12:04:40 AM

Jason Gill  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

NIH Grant Management Officer



**SECTION I – AWARD DATA – 2R01CA120528-11A1****Award Calculation (U.S. Dollars)**

Federal Direct Costs  
Federal F&A Costs  
Approved Budget  
Total Amount of Federal Funds Obligated (Federal Share)  
**TOTAL FEDERAL AWARD AMOUNT**

**AMOUNT OF THIS ACTION (FEDERAL SHARE)**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
11		
12		
13		
14		
15		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

CFDA Name: Cancer Detection and Diagnosis Research  
CFDA Number: 93.394  
EIN: 1042312909A1  
Document Number: RCA120528C  
PMS Account Type: P (Subaccount)  
Fiscal Year: 2017

IC	CAN	2017	2018	2019	2020	2021
CA	8479566					

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: K2DR / OC: 414B / Released: GILLJO 08/08/2017  
Award Processed: 08/14/2017 12:04:39 AM

**SECTION II – PAYMENT/HOTLINE INFORMATION – 2R01CA120528-11A1**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

**SECTION III – TERMS AND CONDITIONS – 2R01CA120528-11A1**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

Page-3

NIH NGA R / Version: 1 - 06/23/2017 11:27:00; Generated on: 8/14/2017 12:04:40 AM

Award Finance Information. Additional subcontract information, if applicable, will be listed below this information.

Projected future year(s) total award amounts.

**IMPORTANT:** Terms and conditions should be reviewed carefully by PI. Note: This is typically where key personnel are listed, meaning prior approval is required if there is a significant effort change of 25% or more.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

Unobligated balance carry-forward information.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

SNAP = Progress Report

This award has been assigned the Federal Award Identification Number (FAIN) R01CA120528. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the "responsible party" must register "applicable clinical trials" on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see [http://grants.nih.gov/ClinicalTrials\\_fdaaa/](http://grants.nih.gov/ClinicalTrials_fdaaa/)

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**  
Additional Costs

---

#### SECTION IV – CA Special Terms and Conditions – 2R01CA120528-11A1

**INFORMATION:** In accordance with the National Cancer Institute's (NCI) policy, "Policy for Allowable Requested Budget Levels of Renewal (Type 2) R01, U01 and P01 Applications" announced in the NIH Guide for Grants and Contracts on August 15, 2008: [\(NOT-CA-08-026\)](#) the allowable Type 2 Cap for this award has been calculated at \$225,000.

In accordance with the National Cancer Institute's (NCI's) Fiscal Year (FY) 2017 funding policies, this award has been issued at 95% of the allowable Type 2 cap level.

\*Spreadsheets used to calculate this award are available upon request.

**INFORMATION:** This project involves hazardous or potentially hazardous agents. Attention is called to the Health and Safety Regulations and Guidelines (Section 4.1.12) of the [NIH Grants Policy Statement](#).

**INFORMATION:** This is a Modular Grant Award issued without direct cost categorical breakdowns in accordance with the guidelines published in the [National Institutes of Health Grants Policy Statement, \(November 2016\)](#). Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

**INFORMATION:** This award involves Human Subjects Research. See "Assurance Requirements and Institutional Review Boards" under Part II, Subpart A, Human Subjects, in the [NIH Grants Policy Statement](#), for specific requirements and grantee responsibilities related to the protection of human subjects, which are applicable to and are a term and condition of this award.

This award reflects the National Cancer Institute's acceptance of the certification that all key personnel have completed education on the protection of human subjects, in accordance the [NIH Grants Policy Statement](#), "Education in the Protection of Human Research Subjects."

Any individual involved in the design and conduct of the study that is not included in the certification must satisfy this requirement prior to participating in the project. Failure to comply can result in the suspension and/or termination of this award, withholding of support of the continuation award, audit disallowances, and/or other appropriate action.

**INFORMATION:** Although the budget period start date for this award is 8/14/17, this award includes funds for twelve months of support. Future year budget periods will cycle on 8/1. Allowable preaward costs may be charged to this award, in accordance with the conditions in the [NIH Grants Policy Statement \(November 2016\)](#), and with institutional requirements for prior approval.

**INFORMATION:** This award, including the budget and the budget period, has been discussed between Jake Pritchard of the National Cancer Institute and Marilyn Gross on 7/15/17.

#### STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Jake Pritchard  
**Email:** [jake.pritchard@nih.gov](mailto:jake.pritchard@nih.gov) **Phone:** (240) 276-6300

**Program Official:** Kelly Y. Kim  
**Email:** [kimke@mail.nih.gov](mailto:kimke@mail.nih.gov) **Phone:** 240.276.5938

**SPREADSHEET SUMMARY**  
**GRANT NUMBER:** 2R01CA120528-11A1

**INSTITUTION:** BRIGHAM AND WOMEN'S HOSPITAL

NIH Contact Information.

Budget	Year 11	Year 12	Year 13	Year 14	Year 15
TOTAL FEDERAL DC					
TOTAL FEDERAL F&A					
TOTAL COST					

Facilities and Administrative Costs	Year 11	Year 12	Year 13	Year 14	Year 15
F&A Cost Rate 1					
F&A Cost Base 1					
F&A Costs 1					